bluebird bio, Inc. (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 1,250 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $95.41, for a total transaction of $119,262.50. Following the sale, the insider now owns 28,555 shares of the company’s stock, valued at approximately $2,724,432.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
bluebird bio, Inc. (NASDAQ BLUE) traded up 2.82% during trading on Monday, hitting $96.60. 427,482 shares of the stock were exchanged. bluebird bio, Inc. has a 1-year low of $37.05 and a 1-year high of $123.75. The company has a 50-day moving average price of $98.08 and a 200 day moving average price of $90.65. The firm’s market capitalization is $4.40 billion.
bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by $0.07. The firm had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company’s revenue was up 977.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.59) earnings per share. Equities analysts predict that bluebird bio, Inc. will post ($6.78) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/bluebird-bio-inc-nasdaqblue-insider-sells-119262-50-in-stock/1468010.html.
Large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its stake in bluebird bio by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 68,220 shares of the biotechnology company’s stock valued at $4,210,000 after buying an additional 540 shares in the last quarter. Macquarie Group Ltd. purchased a new stake in bluebird bio during the fourth quarter valued at about $703,000. Candriam Luxembourg S.C.A. raised its stake in shares of bluebird bio by 17.5% in the first quarter. Candriam Luxembourg S.C.A. now owns 161,000 shares of the biotechnology company’s stock worth $14,636,000 after buying an additional 24,000 shares during the period. First Mercantile Trust Co. raised its stake in shares of bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock worth $263,000 after buying an additional 365 shares during the period. Finally, Strs Ohio raised its stake in shares of bluebird bio by 40.5% in the first quarter. Strs Ohio now owns 5,900 shares of the biotechnology company’s stock worth $536,000 after buying an additional 1,700 shares during the period.
Several research firms have recently weighed in on BLUE. BTIG Research reiterated a “buy” rating and issued a $112.00 target price on shares of bluebird bio in a research note on Thursday, June 1st. Zacks Investment Research downgraded shares of bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. BidaskClub downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $88.00 target price on shares of bluebird bio in a research note on Friday. Finally, Maxim Group upgraded shares of bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Friday, June 2nd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the stock. bluebird bio currently has a consensus rating of “Hold” and an average price target of $100.66.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with our FREE daily email newsletter.